Table 2.
Clinical trials with CAR-T-cell therapy for HER2-positive tumors: (clinicaltrials.gov, accessed on 12 October 2022).
| NCT Number | Study Title | Study Status | Conditions | Interventions | Phases |
|---|---|---|---|---|---|
| NCT03267173 | Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer. | UNKNOWN | Pancreatic Cancer | Drug: Mesothelin, PSCA, CEA, HER2, MUC1, EGFRvIII targeted and other CAR-T cell | EARLY_PHASE1 |
| NCT02547961 | Chimeric Antigen Receptor-Modified T Cells for Breast Cancer | WITHDRAWN (Project terminated due to revision of local regulations) | Breast Cancer | BIOLOGICAL: HER2-targeted CAR-T cells | PHASE1|PHASE2 |
| NCT04511871 | A Phase I Trial of CCT303-406 in Patients with Relapsed or Refractory HER2 Positive Solid Tumors | RECRUITING | Solid Tumor, Gastric Cancer, Breast Cancer, Ovarian Cancer, Sarcoma | BIOLOGICAL: HER2-targeted CAR-T cells | PHASE1 |
| NCT04903080 | HER2-specific Chimeric Antigen Receptor (CAR) T Cells for Children with Ependymoma | RECRUITING | Ependymoma | BIOLOGICAL: HER2-targeted CAR-T cells | PHASE1 |
| NCT00902044 | Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma | ACTIVE_NOT_RECRUITING | Sarcoma | GENETIC: Autologous HER2-targeted CAR-T cells, DRUG: Fludarabine, DRUG: Cyclophosphamide | PHASE1 |
| NCT02713984 | A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer | WITHDRAWN (Reform CAR structure due to safety consideration) | Breast Cancer, Ovarian Cancer, Lung Cancer, Gastric Cancer, Colorectal Cancer, Glioma, Pancreatic Cancer | BIOLOGICAL: HER2-targeted CAR-T cells | PHASE1, PHASE2 |
| NCT03389230 | Memory-Enriched T Cells in Treating Patients with Recurrent or Refractory Grade III-IV Glioma | RECRUITING | Glioblastoma, Malignant Glioma, Recurrent Glioma, Refractory Glioma, WHO Grade III Glioma | BIOLOGICAL: HER2-targeted CAR-T cells | PHASE1 |
| NCT03696030 | HER2-CAR T Cells in Treating Patients with Recurrent Brain or Leptomeningeal Metastases | RECRUITING | Malignant Neoplasm, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Neoplasm in the Leptomeninges, Breast Cancer, HER2-positive Breast Cancer | BIOLOGICAL: HER2-targeted CAR-T cells | PHASE1 |
| NCT04650451 | Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects with HER2-Positive Solid Tumors | RECRUITING | HER-2 Gene Amplification, HER2-positive Gastric Cancer, HER2-positive Breast Cancer, HER-2 Protein Overexpression, Solid Tumor, Adult | BIOLOGICAL: HER2-targeted CAR-T cells | PHASE1 |
| NCT03740256 | Binary Oncolytic Adenovirus in Combination with HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors | RECRUITING | Bladder Cancer, Head and Neck Squamous Cell Carcinoma, Cancer of the Salivary Gland, Lung Cancer, Breast Cancer, Gastric Cancer, Esophageal Cancer, Colorectal Cancer, Pancreatic Adenocarcinoma, Solid Tumor | BIOLOGICAL: HER2-targeted CAR-T cells | PHASE1 |
| NCT04995003 | HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination with Checkpoint Blockade in Patients with Advanced Sarcoma | RECRUITING | Sarcoma, HER-2 Protein Overexpression | GENETIC: HER2-targeted CAR-T cells, DRUG: Pembrolizumab, DRUG: Nivolumab, DRUG: Lymphodepletion Chemotherapy | PHASE1 |
| NCT04684459 | Dual-targeting HER2 and PD-L1 CAR-T for Cancers with Pleural or Peritoneal Metastasis | RECRUITING | Peritoneal Carcinoma Metastatic, Pleural Effusion, Malignant | BIOLOGICAL: Dual-targeting HER2 and PD-L1 CAR-T cells | EARLY_PHASE1 |
| NCT00889954 | Her2 and TGFBeta Cytotoxic T Cells in Treatment of Her2 Positive Malignancy | COMPLETED | HER2 Positive Malignancies | BIOLOGICAL: TGFBeta resistant HER2/EBV-CTLs (CAR-T cells) | PHASE1 |
| NCT00924287 | Gene Therapy Using Anti-Her-2 Cells to Treat Metastatic Cancer | TERMINATED (This study was terminated after the first patient treated on study died as a result of the treatment.) | Metastatic Cancer | DRUG: HER2-targeted CAR-T cells plus IV IL-2, DRUG: Cyclophosphamide, DRUG: Fludarabine, DRUG: Mesna | PHASE1, PHASE2 |
| NCT02442297 | T Cells Expressing HER2-specific Chimeric Antigen Receptors (CAR) for Patients with HER2-Positive CNS Tumors | RECRUITING | Brain Tumor, Recurrent, Brain Tumor, Refractory | BIOLOGICAL: HER2-targeted CAR-T cells | PHASE1 |
| NCT04430595 | Multi-4SCAR-T Therapy Targeting Breast Cancer | RECRUITING | Breast Cancer | BIOLOGICAL: multiple 4th generation CAR-T cells targeted Her2, GD2, and CD44v6 | PHASE1, PHASE2 |
| NCT01109095 | CMV-specific Cytotoxic T Lymphocytes Expressing CAR Targeting HER2 in Patients with GBM | COMPLETED | Glioblastoma Multiforme (GBM) | BIOLOGICAL: HER2-targeted CAR CMV-specific CTLs (CMV-specific cytotoxic T cells) | PHASE1 |
| NCT03500991 | HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors | RECRUITING | Central Nervous System Tumor, Pediatric, Glioma, Ependymoma, Medulloblastoma, Germ Cell Tumor, Atypical Teratoid/Rhabdoid Tumor, Primitive Neuroectodermal Tumor, Choroid Plexus Carcinoma, Pineoblastoma | BIOLOGICAL: HER2-targeted CAR-T cells | PHASE1 |
| NCT03198052 | PSCA/MUC1/TGFOI/HER2/Mesothelin/Lewis-Y/GPC3/AXL/EGFR/B7-H3/Claudin18.2-CAR-T Cells Immunotherapy Against Cancers | RECRUITING | Lung Cancer, Cancer, Immunotherapy, CAR-T Cell | BIOLOGICAL: CAR-T cells targeting PSCA, MUC1, TGFOI, HER2, Mesothelin, Lewis-Y, GPC3, AXL, EGFR, Claudin18.2, or B7-H3 | PHASE1 |